Funding for new RCT in migraine
The Nordic Chronic Migraine Trial of CGRP monoclonal antibody and onabotulinumtoxin A dual therapy – a randomized-controlled double-blind trial (NorMig) – a new RCT led by Aamodt was awarded 9 mill NOK from the South Eastern Health Authority in December 2023
Individuell-innstillingsliste-tematisk-apen.pdf